(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection...
Stats | |
---|---|
今日成交量 | 1 121.00 |
平均成交量 | 714.00 |
市值 | 267.33B |
EPS | €0 ( 2024-04-26 ) |
下一个收益日期 | ( €0 ) 2024-07-25 |
Last Dividend | €1.480 ( 2023-07-13 ) |
Next Dividend | €0 ( N/A ) |
P/E | 59.44 |
ATR14 | €0.890 (0.59%) |
Abbvie Inc 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Abbvie Inc 财务报表
Annual | 2023 |
营收: | €54.32B |
毛利润: | €33.90B (62.42 %) |
EPS: | €2.75 |
FY | 2023 |
营收: | €54.32B |
毛利润: | €33.90B (62.42 %) |
EPS: | €2.75 |
FY | 2022 |
营收: | €58.05B |
毛利润: | €40.64B (70.00 %) |
EPS: | €6.69 |
FY | 2021 |
营收: | €56.20B |
毛利润: | €38.75B (68.96 %) |
EPS: | €6.92 |
Financial Reports:
No articles found.
Abbvie Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€1.410 (N/A) |
€1.410 (N/A) |
€1.480 (N/A) |
€1.480 (N/A) |
€1.480 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.570 | 2016-07-13 |
Last Dividend | €1.480 | 2023-07-13 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 23 | -- |
Total Paid Out | €24.73 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.02 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.62 | |
Div. Directional Score | 7.62 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
RWE.DE | Ex Dividend Junior | 2023-05-05 | Annually | 0 | 0.00% | |
CAR.DE | Ex Dividend Knight | 2023-06-06 | Annually | 0 | 0.00% | |
KEL.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
TIMA.DE | Ex Dividend Junior | 2023-05-10 | Annually | 0 | 0.00% | |
DMP.DE | Ex Dividend Knight | 2023-06-15 | Annually | 0 | 0.00% | |
MTE.DE | Ex Dividend Junior | 2023-07-07 | Quarterly | 0 | 0.00% | |
68V.DE | Ex Dividend Knight | 2023-08-07 | Quarterly | 0 | 0.00% | |
WAF.DE | Ex Dividend Junior | 2023-05-08 | Annually | 0 | 0.00% | |
FIE.DE | Ex Dividend Junior | 2023-07-14 | Annually | 0 | 0.00% | |
PAH3.DE | Ex Dividend Knight | 2023-07-03 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0895 | 1.500 | 8.21 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0361 | 1.200 | 8.80 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.400 | 1.500 | 6.66 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 2.17 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0.872 | 0.800 | -0.639 | -0.512 | [1 - 3] |
quickRatioTTM | 0.633 | 0.800 | -0.980 | -0.784 | [0.8 - 2.5] |
cashRatioTTM | 0.339 | 1.500 | 9.23 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.441 | -1.500 | 2.65 | -3.98 | [0 - 0.6] |
interestCoverageTTM | 3.35 | 1.000 | 9.87 | 9.87 | [3 - 30] |
operatingCashFlowPerShareTTM | 12.93 | 2.00 | 5.69 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 12.49 | 2.00 | 3.75 | 7.51 | [0 - 20] |
debtEquityRatioTTM | 5.73 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.624 | 1.000 | 2.93 | 2.93 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.235 | 1.000 | 7.30 | 7.30 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.385 | 1.000 | 8.97 | 8.97 | [0.2 - 2] |
assetTurnoverTTM | 0.403 | 0.800 | -0.645 | -0.516 | [0.5 - 2] |
Total Score | 10.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 58.66 | 1.000 | 4.18 | 0 | [1 - 100] |
returnOnEquityTTM | 0.400 | 2.50 | 7.86 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 12.49 | 2.00 | 5.84 | 7.51 | [0 - 30] |
dividendYielPercentageTTM | 4.71 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 12.93 | 2.00 | 5.69 | 10.00 | [0 - 30] |
payoutRatioTTM | 2.17 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | -1.078 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.420 | 1.000 | 1.988 | 0 | [0.1 - 0.5] |
Total Score | 4.62 |
Abbvie Inc
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。